✓ Graphs ✓ Tables ✓ Reports
 
Format: www.xyz.com or *.gov
Where ▼
Where ▲
Date:
Note: Results will be PDF and Excel – which we can date reliably. For PDFs, it will either be the date the PDF was creater, or the date visible in the graph or chart.
When ▼
When ▲
What ▼
What ▲

Data & statistics on Cellular Therapy Oncology Drug – 5784 results
Hover over me
TriMix: A new cellular therapy for skin cancer

TriMix: A new cellular therapy for skin cancer

rd-ir.vub.ac.be/en_GB/editor-file/read/x/ALL_2_default_2607/y/560a213967f6340016cc0ce06e314d46/file/TTI%2520kalender2012bijnafinaal.pdf

Vrije Universiteit Brussel Laboratory for Molecular and Cellular Therapy (LMCT ...
/ deliberation study period exams TriMix: A new cellular therapy for skin cancer Over the past few years, cellular therapy and antigen specific immunotherapy have emerged

Jan 2012 | Vrije Universiteit Brussel - Research and Development
Original Url: http://rd-ir.vub.ac.be/en_GB/editor-file/read/x/ALL_2_default_2607/y/560a213967f6340016cc0ce06e314d46/file/TTI%2520kalender2012bijnafinaal.pdf
Oncology Project Survival: Based on project survival data in DEVELOPMENT optimizer, there is a large difference between projects surviving past Phase II in oncology versus all other therapeutic areas. 21% of oncology drug projects “survive” to Phase III versus 43% of all other projects, and oncology projects are approved slightly less than half as often as other projects.

Oncology Project Survival: Based on project survival data in DEVELOPMENT optimizer, there is a large difference between projects surviving past Phase II in oncology versus all other therapeutic areas ...

www.recap.com/pdf/reviews/Q3_10_Clinical_Review.pdf

Note: Attrition by Project charts show projects that are either terminated (in red) at that Phase or proceed to the next Phase (in blue). This graph portrays only projects that have either been terminated OR reached market – ongoing development ...

Dec 2010 | Deloitte Recap LLC: biopharma business intelligence subscription tools and consulting services
Original Url: http://www.recap.com/pdf/reviews/Q3_10_Clinical_Review.pdf
Oncology Therapeutics • 300 drugs FDA approved for anti-cancer therapy • Approx 400 anticancer drugs in development

Oncology Therapeutics • 300 drugs FDA approved for anti-cancer therapy • Approx 400 anticancer drugs in development

www.ascpt.org/annualmeeting2009/presentations/031909/publicpolicysession.pdf

Oncology Off Label Use What data is there concerning prevalence off label drug use in Oncology? • Observational data • Chart surveys • Prescriber questionnaires ...
Introduction • Global cancer drug sales projected $80 billion by 2012 Ph

Apr 2009 | ASCPT - Welcome
Original Url: http://www.ascpt.org/annualmeeting2009/presentations/031909/publicpolicysession.pdf
Top therapeutic segments: Oncology has remained the largest therapeutic segment globally in the last few years and is expected to grow to market size of US$75-80 billion by 2015 growing at a CAGR of 5-8% which is considerably slower compared to its growth in the last few years. Major demand drivers for oncology segment are potential in pharma emerging markets, novel mechanisms, research and development ...

Top therapeutic segments: Oncology has remained the largest therapeutic segment globally in the last few years and is expected to grow to market size of US$75-80 billion by 2015 growing at a CAGR of 5 ...

www.aanlife.com/pdf/draft_offering_circular.pdf

DRUG TYPES Patented Drugs and Generic Equivalents: When a pharmaceutical company develops a new medication typically known as a New Chemical Entity (“NCE”), it ...
in getting an approval for this NCE as a drug, then it has exclusive rights to market

Jan 2015 | Aanjaneya Lifecare Limited
Original Url: http://www.aanlife.com/pdf/draft_offering_circular.pdf
University of Chicago Department of Radiation and Cellular Oncology : 3D Conformal Radiation Therapy

University of Chicago Department of Radiation and Cellular Oncology : 3D Conformal Radiation Therapy

www.radonc.uchicago.edu/typea/tec_3d-conformal.html

University of Chicago Department of Radiation and Cellular Oncology : 3D Conformal Radiation Therapy

Oct 2005 | www.radonc.uchicago.edu
Activity Name Start End Location *If no hours are indicated then program has not been reviewed *If there is a "0" in the column then this seminar has not been approved for hours in that area. Cranial Laser Reflex Technique Cranial Laser Reflex Technique CranialSacral Therapy III CranioSacral Therapy I CranioSacral Therapy I CranioSacral Therapy II 11-149 CranioSacral Therapy III CTCA Spring Oncology ...

Activity Name Start End Location *If no hours are indicated then program has not been reviewed *If there is a "0" in the column then this seminar has not been approved for hours in that area. Cranial ...

oregonsurplus.com/OBNM/CEPage/2011ApprovedCEAlpha.pdf

Reflex Technique CranialSacral Therapy III CranioSacral Therapy I CranioSacral Therapy I CranioSacral Therapy II 11-149 CranioSacral Therapy III CTCA Spring Oncology ...
Depletions PDP- Drugs That Don't Work NCNM- and Natural Therapies that Do Drugs That Don

Jan 2013 | State of Oregon: State & Federal Surplus Property
Original Url: http://oregonsurplus.com/OBNM/CEPage/2011ApprovedCEAlpha.pdf
According to the CPA, the three therapeutic classes with the highest average annual hospital market growth between 2005 and 2009 are oncology and immuno-regulatory agents, nervous system drugs and digestive system and metabolism drugs with 26.94%, 26.57% and 20.29% respectively.
9 more results from this site ▶

According to the CPA, the three therapeutic classes with the highest average annual hospital market growth between 2005 and 2009 are oncology and immuno-regulatory agents, nervous system drugs and ...

www.pharmachinaonline.com/upfiles/UploadFiles/20107301307722.pdf

Association (CPA), growth of the Chinese hospital drug purchase slowed to 12. 67% in the first half of 2009, and the drug purchase by representative hospitals monitored

Jan 2009 | WiCON | Pharma China (Web Edition) – 9 more results from this site
Original Url: http://www.pharmachinaonline.com/upfiles/UploadFiles/20107301307722.pdf
Cancer Epidemiology, Biomarkers & Prevention Cancer Letters (Print) Cell Research Chemical Research in Toxicology Clinical and Experimental Allergy (Print) Clinical Immunology (Orlando, Fla. Print) Clinical Microbiology and Infection (Print) Conservation Biology Critical Reviews in Biotechnology Critical Reviews in Oncology/Hematology Current Drug Targets (Print) Current Gene Therapy Current Medicinal ...

Cancer Epidemiology, Biomarkers & Prevention Cancer Letters (Print) Cell Research Chemical Research in Toxicology Clinical and Experimental Allergy (Print) Clinical Immunology (Orlando, Fla. Print) ...

www.uezo.rj.gov.br/propesq/mestrado/PDF/Biotecnologia.pdf

Conservation Biology Critical Reviews in Biotechnology Critical Reviews in Oncology/Hematology Current Drug Targets (Print) Current Gene Therapy Current Medicinal Chemistry Current Opinion in Infectious Diseases Current Opinion in Oncology Current

Jan 2012 | Portal do Governo do Estado do Rio de Janeiro
Original Url: http://www.uezo.rj.gov.br/propesq/mestrado/PDF/Biotecnologia.pdf
Downloaded from jco.ascopubs.org on February 9, 2011. For personal use only. No other uses without permission. Copyright © 2000 American Society of Clinical Oncology. All rights reserved.
349 more results from this site ▶

Downloaded from jco.ascopubs.org on February 9, 2011. For personal use only. No other uses without permission. Copyright © 2000 American Society of Clinical Oncology. All rights reserved.

jco.ascopubs.org/content/18/17/3135.full.pdf

in these patients’ prior course of rituximab therapy (12.4 and 9.8 months, respectively ...
patients to avoid cytotoxic therapies for years. In the postmarketing experience ...
treatment with all other available therapies. However, sufficient information

Jan 2011 | Journal of Clinical Oncology – 349 more results from this site
Original Url: http://jco.ascopubs.org/content/18/17/3135.full.pdf
Chemotherapy Drugs £49k under-recovered, Clinical Oncology £43k under-recovered (Activity), Offset by Therapies Outpatient over-performance £28k, Clinical Haematology £35k and Audiology £14k

Chemotherapy Drugs £49k under-recovered, Clinical Oncology £43k under-recovered (Activity), Offset by Therapies Outpatient over-performance £28k, Clinical Haematology £35k and Audiology £14k

www.midstaffs.nhs.uk/aboutUs/corporate/minutes/agendas/290710/Enc09-5-1.pdf

Path Labs Pharmacy Therapy Others (1) (93) (200) NON PAY Cancer Services Drugs £6k underspend net effect from overspend on Clinical Haematology Drugs and underspend on Chemotherapy drugs Reduction in Medica spend offset by contrast media price increase (13

Jan 2011 | Mid Staffordshire NHS Foundation Trus
Original Url: http://www.midstaffs.nhs.uk/aboutUs/corporate/minutes/agendas/290710/Enc09-5-1.pdf
Related searches: cytokine therapy oncology drug, angiogenesis oncology drug, autoimmune diseases therapy, breast cancer therapy, brain tumor therapy

Hints & help

Language. English only please... for now.
Phrase search. You can use double quotes to make phrases (e.g. "mobile phones").
Booleans. You can use a plus ‘+’ to make a word mandatory, or a minus ‘–‘ to exclude it (e.g. +gas –oil production)
Vocabulary. We have only limited synonyms - please try different words in your query.
Questions? Please email us: helpdesk [at] zanran [dot] com